SUNPHARMA.NSE logo

SUNPHARMA.NSE
Sun Pharmaceutical Industries Ltd.

6,622
Loading...
Loading...
News
all
press releases
Indian Pharma Billionaires Pile Into Generic Weight-Loss Drugs, Sparking Regulatory Scrutiny
… Dilip Shanghvi’s Sun Pharmaceutical Industries introduced semaglutide pen injections … stepping up scrutiny of the new drugs . “With the recent introduction of … strictures against the promotion of these drugs prohibiting “surrogate advertisements and …
cityfalcon.com·2d ago
News Placeholder
More News
News Placeholder
SunPharma’s ‘HeartkeLiye8–Making India Heart Strong’ campaign urges Indians to prioritise heart health through daily actions
As India’s No. 1* pharmaceutical company in the cardio-metabolic therapy, Sun Pharma plays a significant role in addressing the growing burden of cardiovascular diseases,with strong leadership across lipid-lowering therapies and a substantial presence in anti-hypertensive and oral anti-diabetes treatments.
cityfalcon.com·2d ago
News Placeholder
Sun Pharma to Present ILUMYA, LEQSELVI, WINLEVI Data at AAD 2026, Showcases Dermatology Advances
New Delhi: Sun Pharmaceutical Industries Limited has announced that … immunology portfolio in detail. Sun Pharma emphasized that these presentations reinforce … patient-centered research approaches. Sun Pharmaceutical Industries Limited, headquartered in India …
cityfalcon.com·3d ago
News Placeholder
Ajanta Pharma, Sun Pharma poised to tap GLP-1 opportunity amid market shift: Siddhartha Khemka
India's metabolic therapy market is transforming post-semaglutide patent expiry, shifting to a competitive, volume-driven model. With significant price drops and increased launches, demand is surging among millions needing obesity management. Broader specialist adoption and a growing prescriber base are fueling this expansion, promising substantial market growth.
cityfalcon.com·5d ago
News Placeholder
GLP-1 impact: Jefferies sees these 3 stocks as winners in the race for Ozempic, Wegovy generics
Indian drug makers are launching affordable generic Semaglutide, the active ingredient in popular weight-loss drugs. Sun Pharma, Lupin, and Torrent Pharma are identified as potential market leaders. Despite initial stockouts online, companies are adjusting supply. The market for these diabetes and obesity drugs is expected to grow significantly in India.
cityfalcon.com·6d ago
<
...
1
>

Latest SUNPHARMA.NSE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.